Nuvalent was acquired by GSK plc in a landmark multi-billion-dollar transaction valued at approximately $10.6 billion. This strategic acquisition successfully integrated Nuvalent's advanced pipeline of precision lung cancer assets—including zidesamtinib and neladalkib—into GSK's expanding global specialty oncology portfolio.